Press offices

Press offices

SMC Spain amplifies the voices of experts on controversial current affairs.

¿Qué me ofrece?

Sources who collaborate with us will multiply their national and international media impact. Register your office to be part of a directory on this website that journalists will be able to consult. Our guides on communication and science can help you in your daily work.

Icono
Cómo trabajamos

When we contact a source that is part of your institution, we will inform you. We will contact you when we organise briefings with scientists from your organisation. We will provide with support resources to facilitate your work. You can find out more about how we work here.   

Título qué me ofrece
What we offer you
Título cómo trabajamos
How we work

Reactions to the first controlled asteroid impact

As planned, the DART (Double Asteroid Redirect Test) mission has hit the asteroid Dimorphos, which orbits a larger asteroid, Didymos. Neither is a threat to Earth. This is the first planetary defence test mission designed to change the orbit of an asteroid, launched by NASA and the Johns Hopkins APL laboratory, with Spanish participation. Scientific teams will study with ground-based telescopes how much the orbit of Dimorphos will change around Didymos after the collision.

0

Reactions to planting trees in drylands to fight climate change

A study published in Science analyses the potential climate benefits of afforestation - both planting trees to create new forests and reforesting old ones - of the world's drylands. The authors show that the cooling effect of afforestation of this vast area would only amount to a decrease of about 1 % of projected greenhouse gas emissions in the business-as-usual and medium-emissions climate scenarios.

0

Reaction to clinical trial testing treatment for a form of ALS

The New England Journal of Medicine reports the publication of data from a clinical trial studying the drug Tofersen against a form of Amyotrophic Lateral Sclerosis (ALS) caused by mutations in the SOD1 gene, which accounts for 2% of sporadic ALS. Six months after treatment, some biomarkers of neuronal damage improved, but not the clinical condition of the patients. In an extension of the study, with no placebo group, a slowing of functional loss was observed, although the researchers acknowledge that there are limitations in interpreting this result.

0